Pradžia › Mielofibrozė › Pennsylvania
Mielofibrozė klinikiniai tyrimai Pennsylvania
8 tyrimai dėl Mielofibrozė ieško dalyvių vietose Pennsylvania.
Miestai Pennsylvania
Oficialus tyrimo tekstas (anglų kalba)
A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
- Thomas Jefferson University, Sidney Kimmel Cancer Center, Clinical Trials Office, Philadelphia
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-10-01 · NCT07469891A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
- Thomas Jefferson University, Philadelphia
- University of Pittsburgh Medical Center, Pittsburgh
- Allegheny Health Network Cancer Institute - West Penn Hospital Location, Pittsburgh
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-10-01 · NCT07623161Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
- University of Pennsylvania, Philadelphia
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-23 · NCT05320198A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
- UPMC Hillman Cancer Center ( Site 6004), Pittsburgh
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-04-02 · NCT06351631Two Step Haplo With Radiation Conditioning
- Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadephia
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2025-10-30 · NCT05031897SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Philadelphia
Renkami dalyviaiStebimasis tyrimas
Visi amžiai · Visoms lytims · Atnaujinta 2025-10-28 · NCT03452774Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
- West Penn Hospital, Pittsburgh
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2025-09-25 · NCT06479135Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition
- Fox Chase Cancer Center - Philadelphia, Philadelphia
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2024-05-03 · NCT06218628Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.